Primary Hyperoxaluria in Children

  • Pierre Cochat
  • Neville Jamieson
  • Cecile Acquaviva-Bourdain
Living reference work entry


Hyperoxaluria may be either a secondary or a primary disease. Three distinct autosomal recessive inherited enzyme defects of glyoxylate metabolism have been related to type 1, type 2, and type 3 primary hyperoxalurias (PH), i.e., alanine: glyoxylate aminotransferase (AGT), glyoxylate reductase/hydroxypyruvate reductase (GRHPR), and 4-hydroxy-2-oxoglutarate aldolase (HOGA), respectively; in addition, a few other patients with PH have been reported without identification of PH1, PH2, nor PH3 so that other rare metabolic defects are likely to exist. Among all PH patients, type 1 accounts for 73–80 %, type 2 for 5–10 %, type 3 for 8–10 %, and others for 5–11 % [1]. The global survival rate is better for PH3 than PH2 and better for PH2 than PH1.


Calcium Oxalate Lanthanum Carbonate Primary Hyperoxaluria Urinary Oxalate Excretion Preimplantation Diagnosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Hoppe B. An update on primary hyperoxaluria. Nat Rev Nephrol. 2012;8:467–75.PubMedCrossRefGoogle Scholar
  2. 2.
    Rumsby G, Cochat P. Primary hyperoxaluria (authors’ reply). N Engl J Med. 2013;369:2163.PubMedCrossRefGoogle Scholar
  3. 3.
    Cochat P, Hulton SA, Acquaviva C, Danpure CJ, Daudon M, De Marchi M, Fargue S, Groothoff J, Harambat J, Hoppe B, Jamieson NV, Kemper MJ, Mandrile G, Marangella M, Picca S, Rumsby G, Salido E, Straub M, van Woerden CS. Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant. 2012;27:1729–36.PubMedCrossRefGoogle Scholar
  4. 4.
    Mulay S, Kulkarni OP, Rupanagudi KV, Migliorini A, Darisipudi MN, Vilaysane A, Muruve D, Shi Y, Munro F, Liapis H, Anders HJ. Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1beta secretion. J Clin Invest. 2013;123:236–46.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Taguchi K, Okada A, Kitamura H, Yasui T, Naiki T, Hamamoto S, Ando R, Mizuno K, Kawai N, Tozawa K, Asano K, Tanaka M, Miyoshi I, Kohri K. Colony-stimulating factor-1 signaling suppresses renal crystal formation. J Am Soc Nephrol. 2014;25:1680–97.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Hoppe B, Kemper MJ, Bokenkamp A, Portale A, Cohn R, Langman C. Plasma calcium oxalate super saturation in children with primary hyperoxaluria and end-stage renal failure. Kidney Int. 1999;56:268–74.PubMedCrossRefGoogle Scholar
  7. 7.
    Stenger KO, Streneck M, Kromminga A. TRACP 5b als ein alternative Marker für Schwere und Fortschreinten der Erkrankung an primärer Hyperoxalurie Typ 1. Nieren- und Hochdruckkrankheiten. 2014;43:217–28.CrossRefGoogle Scholar
  8. 8.
    Beloncle F, Sayegh J, Duveau A, Besson V, Croue A, Subra JF, Augusto JF. An unexpected cause of progressive renal failure in a 66-year-old male after liver transplantation: secondary hyperoxaluria. Int Urol Nephrol. 2013;45:1209–13.PubMedCrossRefGoogle Scholar
  9. 9.
    Beck BB, Hoyer-Kuhn H, Göbel H, Habbig S, Hoppe B. Hyperoxaluria and systemic oxalosis: an update on current therapy and future directions. Expert Opin Investig Drugs. 2013;22:117–29.PubMedCrossRefGoogle Scholar
  10. 10.
    Cochat P, Deloraine A, Rotily M, Olive F, Liponski I, on behalf of the Société de Néphrologie and the Société de Néphrologie Pédiatrique. Epidemiology of primary hyperoxaluria type 1. Nephrol Dial Transplant. 1995;10 Suppl 8:3–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med. 2013;369:648–58.Google Scholar
  12. 12.
    Hoppe B, Langman C. A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria. Pediatr Nephrol. 2003;18:986–91.PubMedCrossRefGoogle Scholar
  13. 13.
    Al-Eisa AA, Samhan M, Naseef M. End-stage renal disease in Kuwaiti children: an 8-year experience. Transplant Proc. 2004;36:1788–91.PubMedCrossRefGoogle Scholar
  14. 14.
    Harambat J, van Stralen KJ, Espinosa L, Groothoff JW, Hulton SA, Cerkauskiene R, Schaefer F, Verrina E, Jager KJ, Cochat P, European Society for Pediatric Nephrology/European Renal Association-European Dialysis and Transplant Association (ESPN/ERA-EDTA) Registry. Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. Clin J Am Soc Nephrol. 2012;7:458–65.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Kamoun A, Lakhoua R. End-stage renal disease of the Tunisian child: epidemiology, etiologies and outcome. Pediatr Nephrol. 1996;10:479–82.PubMedCrossRefGoogle Scholar
  16. 16.
    Almardini RI, Alfarah MG, Salaita GM. The clinical pattern of primary hyperoxaluria in pediatric patients at Queen Rania Abdulla Children Hospital. Arab J Nephrol Transplant. 2014;7:119–23.PubMedGoogle Scholar
  17. 17.
    Tadmouri GO, Nair P, Obeid T, Al Ali MT, Al Khaja N, Hamamy HA. Consanguinity and reproductive health among Arabs. Reprod Health. 2009;6:17–26.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Cochat P, Koch Nogueira PC, Mahmoud AM, Jamieson NV, Scheinman JI, Rolland MO. Primary hyperoxaluria in infants: medical, ethical and economic issues. J Pediatr. 1999;135:746–50.PubMedCrossRefGoogle Scholar
  19. 19.
    Millan MT, Berquist WE, So SK, Sarwal MM, Wayman KI, Cox KL, Filler G, Salvatierra Jr O, Esquivel CO. One hundred percent patient and kidney allograft survival with simultaneous liver and kidney transplantation in infants with primary hyperoxaluria: a single-center experience. Transplantation. 2003;76:1458–63.PubMedCrossRefGoogle Scholar
  20. 20.
    Cochat P, Liutkus A, Fargue S, Basmaison O, Ranchin B, Rolland MO. Primary hyperoxaluria type 1: still challenging! Pediatr Nephrol. 2006;21:1075–81.PubMedCrossRefGoogle Scholar
  21. 21.
    Harambat J, Fargue S, Acquaviva C, Gagnadoux MF, Janssen F, Liutkus A, Mourani C, Macher MA, Abramowicz D, Legendre C, Durrbach A, Tsimaratos M, Nivet H, Girardin E, Schott AM, Rolland MO, Cochat P. Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int. 2010;77:443–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Daudon M, Jungers P. Clinical value of crystalluria and quantitative morphoconstitutional analysis of urinary calculi. Nephron Physiol. 2004;98:31–6.CrossRefGoogle Scholar
  23. 23.
    Barratt TM, Kasidas GP, Murdoch I, Rose GA. Urinary oxalate and glycolate excretion and plasma oxalate concentration. Arch Dis Child. 1991;66:501–3.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Belostotsky R, Pitt J, Frishberg Y. Primary hyperoxaluria type III-a model for studying perturbations in glyoxylate metabolism. J Mol Med. 2012;90:1497–504.PubMedCrossRefGoogle Scholar
  25. 25.
    Dietzen DJ, Wilhite TR, Kenagy DN, Milliner DS, Smith CH, Landt M. Extraction of glyceric and glycolic acids from urine with tetrahydrofuran: utility in detection of primary hyperoxaluria. Clin Chem. 1997;43:1315–20.PubMedGoogle Scholar
  26. 26.
    Pitt JJ, Willis F, Tzanakos N, Belostotsky R, Frishberg Y. 4-hydroxyglutamate is a biomarker for primary hyperoxaluria type 3. JIMD Rep. 2015;15:1–6.PubMedCentralPubMedGoogle Scholar
  27. 27.
    Wong PN, Law ELK, Tong GMW, Mak SK, Lo KY, Wong AKM. Diagnosis of primary hyperoxaluria type 1 by determination of peritoneal dialysate glycolic acid using standard organic-acids analysis method. Perit Dial Int. 2003;23:S210–3.PubMedGoogle Scholar
  28. 28.
    Marangella M, Vitale C, Petrarulo M, Tricerri A, Cerelli E, Cadario A, Barbos MP, Linari F. Bony content of oxalate in patients with primary hyperoxaluria or oxalosis-unrelated renal failure. Kidney Int. 1995;48:182–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Bacchetta J, Boivin G, Cochat P. Bone impairment in primary hyperoxaluria: a review. Pediatr Nephrol. 2015 (in press).Google Scholar
  30. 30.
    Berini SE, Tracy JA, Engelstad JK, Lorenz EC, Milliner DS, Dyck PJ. Progressive polyradiculoneuropathy due to intraneural oxalate deposition in type 1 primary hyperoxaluria. Muscle Nerve. 2015;51:449–54.Google Scholar
  31. 31.
    Williams E, Rumsby G. Selected exonic sequencing of the AGXT gene provides a genetic diagnosis in 50 % of patients with primary hyperoxaluria type 1. Clin Chem. 2007;53:1216–21.PubMedCrossRefGoogle Scholar
  32. 32.
    Fargue S. Factors influencing clinical outcome in patients with primary hyperoxaluria type 1. Kidney Int. 2014;86:1074–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Coulter-Mackie MB, Rumsby G. Genetic heterogeneity in primary hyperoxaluria type 1: impact on diagnosis. Mol Genet Metab. 2004;83:38–46.PubMedCrossRefGoogle Scholar
  34. 34.
    Danpure CJ. Molecular aetiology of primary hyperoxaluria type 1. Nephron Exp Nephrol. 2004;98:e39–44.PubMedCrossRefGoogle Scholar
  35. 35.
    Mandrile G, van Woerden CS, Berchialla P, Beck BB, Acquaviva-Bourdain C, Hulton SA, Rumsby G. on behalf of the OxalEurope Consortium. Data from a large European study indicates that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney Int. 2014;86:1197–204.PubMedCrossRefGoogle Scholar
  36. 36.
    Williams EL, Bagg EAL, Mueller M, Vandrovcova J, Aitman TJ, Rumsby G. Performance evaluation of Sanger sequencing for the diagnosis of primary hyperoxaluria and comparison with targeted next generation sequencing. Mol Genet Genomic Med. 2015;3:69–78.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Coulter-Mackie MB, Applegarth D, Toone JR, Henderson H. The major allele of the alanine: glyoxylate aminotransferase gene: seven novel mutations causing primary hyperoxaluria. Mol Genet Metab. 2004;82:64–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Danpure CJ. Molecular etiology of primary hyperoxaluria type 1: new directions for treatment. Am J Nephrol. 2005;25:303–10.PubMedCrossRefGoogle Scholar
  39. 39.
    Lumb MJ, Danpure CJ. Functional synergism between the most common polymorphism in human alanine: glyoxylate aminotransferase and four of the most common disease-causing mutations. J Biol Chem. 2000;275:36415–22.PubMedCrossRefGoogle Scholar
  40. 40.
    Monico CG, Rossetti S, Olson JB, Milliner DS. Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int. 2005;67:1704–9.PubMedCrossRefGoogle Scholar
  41. 41.
    van Woerden CS, Groothoff JW, Wijburg FA, Annink C, Wanders RJ, Waterham HR. Clinical implications of mutation analysis in primary hyperoxaluria type 1. Kidney Int. 2004;66:746–52.PubMedCrossRefGoogle Scholar
  42. 42.
    Nogueira PC, Vuong TS, Bouton O, Maillard A, Marchand M, Rolland MO, Cochat P, Bozon D. Partial deletion of the AGXT gene (EX1_EX7del): a new genotype in hyperoxaluria type 1. Hum Mutat. 2000;15:384–5.PubMedCrossRefGoogle Scholar
  43. 43.
    Danpure CJ. Primary hyperoxaluria: from gene defects to designer drugs? Nephrol Dial Transplant. 2005;20:1525–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Danpure CJ, Rumsby G. Enzymological and molecular genetics of primary hyperoxaluria type 1. Consequences for clinical management. In: Khan SR, editor. Calcium oxalate in biological systems. Boca Raton: CRC Press; 1995. p. 189–205.Google Scholar
  45. 45.
    Coulter-Mackie MB. Preliminary evidence for ethnic differences in primary hyperoxaluria type 1 genotype. Am J Nephrol. 2005;25:264–8.PubMedCrossRefGoogle Scholar
  46. 46.
    von Schnakenburg C, Hulton SA, Milford DV, Roper HP, Rumsby G. Variable presentation of primary hyperoxaluria type 1 in 2 patients homozygous for a novel combined deletion and insertion mutation in exon 8 of the AGXT gene. Nephron. 1998;78:485–8.CrossRefGoogle Scholar
  47. 47.
    Benhaj Mbarek I, Abroug S, Omezzine A, Zellama D, Achour A, Harbi A, Bouslama A. Selected AGXT gene mutations analysis provides a genetic diagnosis in 28 % of Tunisian patients with primary hyperoxaluria. BMC Nephrol. 2011;12:25–30.PubMedCrossRefGoogle Scholar
  48. 48.
    Alfadhel M, Alhassan KA, Alotaibi M, Fakeeh KA. Extreme intrafamilial variability of Saudi brothers with primary hyperoxaluria type 1. Ther Clin Risk Manag. 2012;8:373–6.PubMedCentralPubMedCrossRefGoogle Scholar
  49. 49.
    Fargue S, Harambat J, Gagnadoux MF, Tsimaratos M, Janssen F, Llanas B, Berthélémé JP, Boudaillez B, Champion G, Guyot C, Macher MA, Nivet H, Ranchin B, Salomon R, Taque S, Rolland MO, Cochat P. Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1. Kidney Int. 2009;76:767–73.PubMedCrossRefGoogle Scholar
  50. 50.
    Leumann E, Hoppe B. The primary hyperoxalurias. J Am Soc Nephrol. 2001;12:1986–93.PubMedGoogle Scholar
  51. 51.
    Behsenhofer LM, Cain MC, Dunning C, McMartin KE. Aluminum citrate prevents renal injury from calcium oxalate crystal deposition. J Am Soc Nephrol. 2012;23:2024–33.CrossRefGoogle Scholar
  52. 52.
    Guo C, Dugas T, Scayes C, Garcia-Villareal M, Ticich T, McMartin KE. Aluminum citrate blocks toxicity of calcium oxalate crystals by preventing binding with cell membrane phospholipids. Am J Nephrol. 2013;37:41–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Baker EM, Saari JC, Tolbert BM. Ascorbic acid metabolism in man ? Am J Clin Nutr. 1966;19:371–8.PubMedGoogle Scholar
  54. 54.
    Massey LK, Liebman M, Kynast-Gales SA. Ascorbate increases human oxaluria and kidney stone risk. J Nutr. 2005;135:1673–7.PubMedGoogle Scholar
  55. 55.
    Sidhu H, Hoppe B, Hesse A, et al. Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria. Lancet. 1998;352:1026–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Hoppe B, Groothoff JW, Hulton SA, et al. Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrol Dial Transplant. 2011;26:3609–15.PubMedCrossRefGoogle Scholar
  57. 57.
    Milliner DS, Wilson DM, Smith LH. Phenotypic expression of primary hyperoxaluria: comparative features of types I and II. Kidney Int. 2001;59:31–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Fargue S, Rumsby G, Danpure CJ. Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1. Biochim Biophys Acta. 2013;1832:1776–83.PubMedCrossRefGoogle Scholar
  59. 59.
    Hoyer-Kuhn H, Kohbrok S, Volland R, et al. Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice. Clin J Am Soc Nephrol. 2014;9:468–77.PubMedCentralPubMedCrossRefGoogle Scholar
  60. 60.
    Gambaro G, Favaro S, D’Angelo A. Risk for renal failure in nephrolithiasis. Am J Kidney Dis. 2001;37:233–43.PubMedCrossRefGoogle Scholar
  61. 61.
    Al-Abadi E, Hulton SA. Extracorporeal shock wave lithotripsy in the management of stones in children with oxalosis – still the first choice? Pediatr Nephrol. 2013;28:1085–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Marangella M, Petrarulo M, Cosseddu D, Vitale C, Linari F. Oxalate balance studies in patients on hemodialysis for type I primary hyperoxaluria. Am J Kidney Dis. 1992;19:546–53.PubMedCrossRefGoogle Scholar
  63. 63.
    Tang X, Voskoboev NV, Wannarka SL, Olson JB, Milliner DS, Lieske JC. Oxalate quantification in hemodialysate to assess dialysis adequacy for primary hyperoxaluria. Am J Nephrol. 2014;39:376–82.PubMedCentralPubMedCrossRefGoogle Scholar
  64. 64.
    Yamauchi T, Quillard M, Takahasi S, Nguyen-Khoa M. Oxalate removal by daily dialysis in a patient with primary hyperoxaluria type 1. Nephrol Dial Transplant. 2001;16:2407–11.PubMedCrossRefGoogle Scholar
  65. 65.
    Behnke B, Kemper MJ, Kruse HP, Müller-Wiefel DE. Bone mineral density in children with primary hyperoxaluria type 1. Nephrol Dial Transplant. 2001;16:2236–9.PubMedCrossRefGoogle Scholar
  66. 66.
    Cibrik DM, Kaplan B, Arndorfer JA, Meier-Kriesche HU. Renal allograft survival in patients with oxalosis. Transplantation. 2002;74:707–10.PubMedCrossRefGoogle Scholar
  67. 67.
    Jamieson NV, Jamieson KA. Primary hyperoxaluria type 1: gene therapy by liver transplantation. Transplantation. 2009;87:1273–4.PubMedCrossRefGoogle Scholar
  68. 68.
    Collard L, Amore A, Bensman A, Bouissou F, Bourdat G, de Ville de Goyet J, Gagnadoux MF, Girardin E, Janssen F, Maisin A, Martini S, Neuhaus T, Novo R, Tsimaratos M, van Damme-Lombaerts R, vande Walle J, Cochat P. Combined liver kidney transplantation in children: multi-centre report. Pediatr Nephrol. 2006;21:1514.Google Scholar
  69. 69.
    Calinescu AM, Wildhaber BE, Poncet A, Toso C, McLin VA. Outcomes of combined liver-kidney transplantation in children: analysis of the scientific registry of transplant recipients. Am J Transplant. 2014;14:2861–8.PubMedCrossRefGoogle Scholar
  70. 70.
    Ellis SR, Hulton SA, McKiernan PJ, de Ville de Goyet J, Kelly DA. Combined liver-kidney transplantation for primary hyperoxaluria in young children. Nephrol Dial Transplant. 2001;16:348–54.PubMedCrossRefGoogle Scholar
  71. 71.
    Sasaki K, Sakamoto S, Uchida H, Shigeta T, Matsunami M, Kanazawa H, Fukuda A, Nakazawa A, Sato M, Ito S, Horikawa R, Yokoi T, Azuma N, Kasahara M. Two-step transplantation for primary hyperoxaluria: a winning strategy to prevent progression of systemic oxalosis in early onset renal insufficiency cases. Pediatr Transplant. 2015;19:E1–6.PubMedCrossRefGoogle Scholar
  72. 72.
    Harps E, Brinkert F, Ganschow R, Briem-Richter A, van Husen M, Schmidtke S, Herden U, Nashan B, Fischer L, Kemper MJ. Immediate postoperative intensive care treatment of pediatric combined liver-kidney transplantation: outcome and prognostic factors. Transplantation. 2011;91:1127–31.PubMedCrossRefGoogle Scholar
  73. 73.
    Cochat P, Schärer K. Should liver transplantation be performed before advanced renal insufficiency in primary hyperoxaluria type 1? Pediatr Nephrol. 1993;7:212–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Kemper MJ. The role of preemptive liver transplantation in primary hyperoxaluria type 1. Urol Res. 2005;33:376–9.PubMedCrossRefGoogle Scholar
  75. 75.
    Hori T, Kaido T, Tamaki N, Toshimitsu Y, Ogawa K, Uemoto S. An adult patient with primary hyperoxaluria regrets not receiving preemptive liver transplantation during childhood: report of a case. Surg Today. 2013;43:1185–7.PubMedCrossRefGoogle Scholar
  76. 76.
    Galanti M, Contreras A. Excellent renal function and reversal of nephrocalcinosis 8 years after isolated liver transplantation in an infant with primary hyperoxaluria type 1. Pediatr Nephrol. 2010;25:2359–62.PubMedCrossRefGoogle Scholar
  77. 77.
    Perera MTPR, Sharif K, Lloyd C, Foster K, Hulton SA, Mirza DF, Mc Kiernan PJ. Pre-emptive liver transplantation for primary hyperoxaluria (PH-I) arrests long-term renal function deterioration. Nephrol Dial Transplant. 2011;26:354–9.PubMedCrossRefGoogle Scholar
  78. 78.
    Brinkert F, Ganschow R, Helmke K, Harps E, Fischer L, Nashan B, Hoppe B, Kulke S, Müller-Wiefel DE, Kemper MJ. Transplantation procedures in children with primary hyperoxaluria type 1: outcomes and longitudinal growth. Transplantation. 2009;87:1415–21.PubMedCrossRefGoogle Scholar
  79. 79.
    Cochat P, Groothoff J. Primary hyperoxaluria type 1: practical and ethical issues. Pediatr Nephrol. 2013;28:2273–81.PubMedCrossRefGoogle Scholar
  80. 80.
    Gagnadoux MF, Lacaille F, Niaudet P, Revillon Y, Jouvet P, Jan D, Guest G, Charbit M, Broyer M. Long term results of liver-kidney transplantation in children with primary hyperoxaluria. Pediatr Nephrol. 2001;16:946–50.PubMedCrossRefGoogle Scholar
  81. 81.
    Simpson N, Cho YW, Cicciarelli JC, Selby RR, Fong TL. Comparison of renal allograft outcomes in combined liver-kidney transplantation versus subsequent kidney transplantation in liver transplant recipients: analysis of UNOS database. Transplantation. 2006;82:1298–303.PubMedCrossRefGoogle Scholar
  82. 82.
    Astarcioglu I, Karademir S, Gulay H, Bora S, Astarcioglu H, Kavuko G, Turkmen M, Soylu A. Primary hyperoxaluria: simultaneous combined liver and kidney transplantation from a living related donor. Liver Transpl. 2003;9:433–6.PubMedCrossRefGoogle Scholar
  83. 83.
    Hori T, Egawa H, Kaido T, Ogawa K, Uemoto S. Liver transplantation for primary hyperoxaluria type 1: a single-center experience during two decades in Japan. World J Surg. 2013;37:688–93.PubMedCrossRefGoogle Scholar
  84. 84.
    Saner FH, Treckmann J, Pratschke J, Arbogast H, Rahmel A, Vester U, Paul A. Early renal failure after domino liver transplantation using organs from donors with primary hyperoxaluria type 1. Transplantation. 2010;90:782–5.PubMedCrossRefGoogle Scholar
  85. 85.
    Miyata N, Steffen J, Johnson ME, Fargue S, Danpure CJ, Koehler CM. Pharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1. Proc Natl Acad Sci USA. 2014;111:14406–11.PubMedCentralPubMedCrossRefGoogle Scholar
  86. 86.
    Jiang J, Salido E, Guha C, Wang X, Moitra R, Liu L, Roy-Chowdhury J, Roy-Chowdhury N. Correction of hyperoxaluria by repopulation with hepatocytes in a mouse model of primary hyperoxaluria type 1. Transplantation. 2008;85:125360.CrossRefGoogle Scholar
  87. 87.
    Beck BB, Habbig S, Dittrich K, Stippel D, Kaul I, Koerber F, Goebel H, Salido E, Kemper M, Meyburg J, Hoppe B. Liver cell transplantation in severe infantile oxalosis – a potential bridging procedure to orthotopic liver transplantation? Nephrol Dial Transplant. 2012;27:2984–9.PubMedCrossRefGoogle Scholar
  88. 88.
    Lukina E, Watman N, Dragosky M, Pastores GM, Arreguin EA, Rosenbaum EH, Zimran A, Angell J, Ross L, Puga AC, Peterschmitt JM. Eliglustat, an investigational oral therapy for Gaucher disease type 1: phase 2 trial results after 4 years of treatment. Blood Cells Mol Dis. 2014;53:274–6.PubMedCrossRefGoogle Scholar
  89. 89.
    Frishberg Y, Zeharia A, Belostotsky R. Mutations in HAO1 encoding glycolate oxidase cause isolated glycolic aciduria. J Med Genet. 2014;51:526–9.PubMedCrossRefGoogle Scholar
  90. 90.
    Giafi CF, Rumsby G. Primary hyperoxaluria type 2: enzymology. J Nephrol. 1998;11 suppl 1:29–31.PubMedGoogle Scholar
  91. 91.
    Mistry J, Danpure CJ, Chalmers RA. Hepatic D-glycerate dehydrogenase and glyoxylate reductase deficiency in primary hyperoxaluria type 2. Biochem Soc Trans. 1988;16:626–7.CrossRefGoogle Scholar
  92. 92.
    Webster KE, Ferree PM, Holmes RP, Cramer SD. Identification of missense, nonsense, and deletion mutations in the GRHPR gene in patients with primary hyperoxaluria type 2. Hum Genet. 2000;107:176–85.PubMedCrossRefGoogle Scholar
  93. 93.
    Giafi CF, Rumsby G. Kinetic analysis and tissue distribution of human D-glycerate dehydrogenase/glyoxylate reductase and its relevance to the diagnosis of primary hyperoxaluria type 2. Ann Clin Biochem. 1998;35:104–9.PubMedCrossRefGoogle Scholar
  94. 94.
    Cramer SD, Ferree PM, Lin K, et al. The gene encoding hydroxypyruvate reductase (GRHPR) is mutated in patients with primary hyperoxaluria type II. Hum Mol Genet. 1999;8:2063–9.PubMedCrossRefGoogle Scholar
  95. 95.
    Cregeen DP, Williams EL, Hulton S, Rumsby G. Molecular analysis of the glyoxylate reductase (GRHPR) gene and description of mutations underlying primary hyperoxaluria type 2. Hum Mutat. 2003;22:497.PubMedCrossRefGoogle Scholar
  96. 96.
    Kemper MJ, Conrad S, Müller-Wiefel DE. Primary hyperoxaluria type 2. Eur J Pediatr. 1997;156:509–12.PubMedCrossRefGoogle Scholar
  97. 97.
    Hoppe B, Leumann E. Diagnosis and therapeutic strategies in hyperoxaluria: a plea for early intervention. Nephrol Dial Transplant. 2004;19:39–42.PubMedCrossRefGoogle Scholar
  98. 98.
    Rashed MS, Aboul-Enein HY, Al Amoudi M, et al. Chiral liquid chromatography tandem mass spectrometry in the determination of configuration of glyceric acid in urine of patients with d-glyceric and l-glyceric acidurias. Biomed Chromatogr. 2002;16:191–8.PubMedCrossRefGoogle Scholar
  99. 99.
    Law CW, Yuen YP, Lai CK, et al. Novel mutation in the GRHPR gene in a Chinese patient with primary hyperoxaluria type 2 requiring renal transplantation from a living related donor. Am J Kidney Dis. 2001;38:1307–10.CrossRefGoogle Scholar
  100. 100.
    Johnson SA, Rumsby G, Cregeen D, Hulton SA. Primary hyperoxaluria type 2 in children. Pediatr Nephrol. 2002;17:597–601.PubMedCrossRefGoogle Scholar
  101. 101.
    Belostotsky R, Seboun E, Idelson GH, Milliner DS, Becker-Cohen R, Rinat C, Monico CG, Feinstein S, Ben-Shalom E, Magen D, Weissman I, Charon C, Frishberg Y. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet. 2010;87:392–9.PubMedCentralPubMedCrossRefGoogle Scholar
  102. 102.
    Hoppe B. The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type III. Nephrol Dial Transplant. 2012;27:3024–6.PubMedCrossRefGoogle Scholar
  103. 103.
    Beck BB, Baasner A, Buescher A, Habbig S, Reintjes N, Kemper MJ, Sikora P, Mache C, Pohl M, Stahl M, Toenshoff B, Pape L, Fehrenbach H, Jacob DE, Grohe B, Wolf MT, Nürnberg G, Yigit G, Salido E, Hoppe B. Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies. Eur J Hum Genet. 2013;21:162–72.PubMedCentralPubMedCrossRefGoogle Scholar
  104. 104.
    Allard L, Bacchetta J, Leclerc AL, Cachat F, Fichtner C, Carla de Souza V, Druck Garcia C, Camoin-Schweitzer MC, Macher MA, Acquaviva-Bourdain C, Cochat P. Renal function can be impaired in children with primary hyperoxaluria type 3. Pediatr Nephrol. (in press).Google Scholar
  105. 105.
    Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, Seide BM, Olson JB, Bergstrahl EJ, Williams HJ, Haley WE, Frishberg Y, Milliner DS. Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol. 2011;6:2289–95.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Pierre Cochat
    • 1
    • 2
  • Neville Jamieson
    • 3
  • Cecile Acquaviva-Bourdain
    • 1
    • 4
  1. 1.Centre de référence des maladies rénales rares Néphrogones, Hôpital Femme Mère EnfantHospices Civils de Lyon & Université de LyonLyonFrance
  2. 2.IBCP-UMR 5305 CNRSUniversité Claude-Bernard Lyon 1LyonFrance
  3. 3.Department of SurgeryAddenbrookes Hospital, Cambridge University Teaching HospitalsCambridgeUnited Kingdom
  4. 4.Service Maladies Héréditaires du Métabolisme et Dépistage Néonatal, Centre de Biologie et Pathologie EstHospices Civils de LyonLyonFrance

Personalised recommendations